Stallion Q2 revenue rose 31.8% as adjusted EBITDA rose 0.43%
Key highlights
- Stallion reported Q2 FY27 revenue of Rs 139.37 crore, up 31.79% year on year.
- Stallion’s Q2 operating EBITDA before ESOP was Rs 15.84 crore, up 0.43%.
- Stallion’s H1 FY27 operating PAT before ESOP rose 40.16% to Rs 30.53 crore.
- Stallion recognised an H1 FY27 non-cash ESOP charge of Rs 9.51 crore for 15,86,505 options.
powered by IRIS

For the quarter ended September 30, 2026, Stallion India Fluorochemicals Limited reported Q2 FY27 revenue of Rs 139.37 crore, up 31.8% year on year, while operating earnings before interest, tax, depreciation and amortisation (EBITDA) before provision for employee stock options (ESOP) rose 0.43% to Rs 15.84 crore.
Know Stallion India Fluorochemicals inside out
Results, valuation, peers and who's buying, in one view.
How did Stallion perform in Q2 FY27?
Stallion delivered higher Q2 FY27 revenue, but operating EBITDA before ESOP was nearly unchanged from Q2 FY25-26. Revenue rose from Rs 105.76 crore to Rs 139.37 crore, whereas operating EBITDA before ESOP rose from Rs 15.77 crore to Rs 15.84 crore.
The comparison shows that revenue increased by Rs 33.61 crore, while operating EBITDA before ESOP increased by Rs 0.07 crore. Operating profit after tax (PAT) before ESOP grew by Rs 0.54 crore, or 4.78%, to Rs 11.96 crore. The release presents both profit measures before the ESOP provision, rather than as statutory post-ESOP profit figures.
Stallion’s Q2 pattern differs from its reported sales expansion because its stated operating EBITDA growth was 0.43%, compared with revenue growth of 31.79%. The release does not provide a segment-wise revenue or cost breakdown for the quarter, so it does not identify which products, selling prices, input costs or operating expenses produced this divergence.
Did first-half performance outpace the quarterly trend?
Stallion’s H1 FY27 operating profit growth before ESOP was materially faster than its Q2 growth, with operating EBITDA before ESOP up 36.39% and PAT before ESOP up 40.16%. H1 total income reached Rs 264.05 crore, a 22.07% increase from Rs 216.30 crore in H1 FY25-26.
The first-half figures represent a different growth profile from Q2. H1 operating EBITDA before ESOP rose by Rs 10.96 crore, while operating PAT before ESOP rose by Rs 8.75 crore. In contrast, Q2 operating EBITDA before ESOP was only Rs 0.07 crore above the comparable prior-year quarter.
H1 revenue growth of 22.07% was lower than Q2 revenue growth of 31.79%, but H1 growth in both disclosed profit measures exceeded the top-line increase. The presentation does not show individual Q1 FY27 figures, so it does not directly quantify the earlier-quarter contribution to the H1 increase in EBITDA and PAT before ESOP.
Got a follow-up? Ask IRIS
How did the ESOP accounting charge affect profit?
Stallion recognised an H1 FY27 ESOP charge of Rs 9.51 crore under Indian Accounting Standard 102, or Ind AS 102, for 15,86,505 employee stock options. The company describes the charge as non-cash and equity-settled, meaning the presentation separates it from the operating EBITDA and PAT figures shown before the provision.
The company says this Ind AS 102 charge is credited to other equity and does not involve a cash outflow. Its stated adjusted measures therefore exclude the Rs 9.51 crore recognised for the options. The release also says the statutory filings continue to comply with Ind AS 102 and that reported results remain unchanged.
This distinction is central to reading the Rs 41.10 crore H1 operating EBITDA before ESOP and Rs 30.53 crore H1 operating PAT before ESOP. Stallion does not provide the corresponding H1 or Q2 reported EBITDA and PAT after the ESOP charge in this presentation, so the size of the accounting effect on each reported profit line cannot be calculated from the supplied figures alone.
What operating milestones and plans did Stallion disclose?
Stallion said its Khalapur high-purity helium facility has commenced operations, is fully operational and is meeting expected volumes for the year. The facility marks the company’s entry into specialty gases for end markets listed as semiconductors, magnetic resonance imaging healthcare, aerospace and defence.
The company also disclosed a global sourcing partnership with SOC Dubai and Qatar for the helium operation. The presentation gives no revenue, capacity, utilisation or profitability figure for Khalapur, so the financial contribution of the facility cannot be measured against the Rs 139.37 crore Q2 revenue reported for FY26-27.
Management said the next steps include ramping up Khalapur’s high-purity semiconductor gas supply, advancing the Mambattu expansion, and progressing R-32 projects for backward integration and portfolio depth. In its November 16, 2026 commentary, management also referred to Mambattu, R-32 and hydrofluoroolefin projects, but disclosed no completion dates, capital expenditure amounts or revenue targets.
Conclusion
Stallion’s presentation shows a clear difference between Q2 sales growth and the growth of its disclosed operating profit measure before ESOP. Revenue increased 31.79% to Rs 139.37 crore, but operating EBITDA before ESOP rose 0.43% to Rs 15.84 crore. Over H1 FY27, however, operating EBITDA before ESOP grew 36.39% to Rs 41.10 crore and PAT before ESOP rose 40.16% to Rs 30.53 crore.
The next disclosed developments to watch are the Khalapur helium ramp-up, the Mambattu expansion and the R-32 backward-integration projects. Management has said the helium facility is meeting expected volumes for the year, but the release provides neither capacity nor financial targets, leaving the pace of contribution from these initiatives unresolved.


